UNITED STATES

SECURITIES AND EXCHANGE COMMISSION



Washington, D.C. 20549

________________

FORM
6-K

________________

 

REPORT OF FOREIGN PRIVATE
ISSUER

Pursuant to Rule 13a-16 or 15d-16

of the Securities Exchange Act of 1934

January 13, 2014

________________

 

        NOVO
NORDISK A/S       

(Exact name of Registrant as specified in its charter) 

Novo
Allé 

DK- 2880, Bagsvaerd 

Denmark

(Address of principal executive offices)

________________

Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F



    Form 20-F [X]      
         Form 40-F [  ]

Indicate by check mark whether the registrant
by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule
12g3-2(b) under the Securities Exchange Act of 1934.



    Yes [  ]     
          No [X]

If “Yes” is marked, indicate below
the file number assigned to the registrant in connection with Rule 12g-32(b):82-_____________________



    
 
    
 
    



 

 

 

 



 

 

 

 

 

 

Novo
Nordisk A/S
– Share repurchase
programme

 

 

 

 

Bagsværd,
Denmark,
13 January
2014 –
On 31
October
2013, Novo
Nordisk
initiated
a share
repurchase
programme
in accordance
with the
provisions
of the
European
Commission’s
regulation
no 2273/2003 of
22 December
2003, also
referred
to as the
Safe Harbour
rules.
This
programme
is part
of the
overall
share
repurchase
programme
of up
to DKK
14.0 billion
to be executed
during
a 12-month
period
beginning
31 January 2013.

 

Under
the programme
initiated
31 October
2013,
Novo
Nordisk
will
repurchase
B shares
for an
amount
up to DKK
2.8 billion
in the
period
from
31 October
2013 to 28
January 2014.

 

Since
the announcement
as of 23
December
2013, the
following
transactions
have been
made under
the programme:



     
    Number of
    Average
    Transaction

     
    shares
    purchase price
    value, DKK

    Accumulated, last announcement
    9,388,055
     
    1,800,000,081

    2 January 2014
    265,000
    200.77
    53,204,792

    3 January 2014
    240,000
    203.66
    48,877,656

    6 January 2014
    275,000
    205.08
    56,396,945

    7 January 2014
    265,000
    205.43
    54,439,613

    8 January 2014
    265,000
    207.51
    54,990,044

    9 January 2014
    265,000
    209.64
    55,553,593

    10 January 2014
    265,000
    210.20
    55,702,417

    Accumulated under the programme
    11,228,055
     
    2,179,165,141

 

With
the transactions
stated
above, Novo
Nordisk owns
a total
of 104,692,025
treasury shares,
corresponding
to 3.8%
of the
share
capital.
The total amount
of shares
in the
company
is 2,750,000,000
including
treasury
shares.

 

 



    Novo Nordisk A/S 
    Novo Allé
    Telephone:
    CVR no:

    Investor Relations 
    2880 Bagsværd
    +45 4444 8888
    24 25 67 90

     
    Denmark
    Internet:
     

     
     
    www.novonordisk.com
     

     
     
     

     
     
    Company announcement No 2 / 2014

     
     
     
     
     



    
 
    
 
    

Page
2 of 2

 

 

 

 

Novo
Nordisk
expects
to repurchase
B shares
for an
amount
up to DKK
14.0 billion
during a 12-month
period
beginning
31 January
2013. As of
10 January 2014,
Novo
Nordisk
has repurchased
a total
of 69,420,270
B shares
equal
to a transaction
value
of DKK
13,366,985,811.

 

 

 

Novo Nordisk
is a global
healthcare company
with 90 years of innovation
and leadership
in diabetes
care. The company
also has leading
positions
within
haemophilia
care, growth
hormone therapy
and hormone replacement
therapy. Headquartered
in Denmark,
Novo Nordisk
employs
approximately
37,000 employees
in 75 countries,
and markets its
products
in more
than 180 countries.
Novo Nordisk’s
B shares are
listed on
NASDAQ
OMX Copenhagen
(Novo-B).
Its ADRs are
listed on
the New York
Stock Exchange
(NVO). For more
information,
visit novonordisk.com.

 

 



    
        
Further
        information
        
Media:
        
Anne
        Margrethe
        Hauge
    
        
 
        
 
        
 
        
+45 4442
        3450
    
        
 
        
 
        
 
        
amhg@novonordisk.com

    Ken Inchausti (US)
    +1 609 514 8316
    kiau@novonordisk.com

    
        
 
        
Investors:
        
Kasper
        Roseeuw
        Poulsen
    
        
 
        
 
        
+45 3079
        4303
    
        
 
        
 
        
krop@novonordisk.com

    Frank Daniel Mersebach
    +45 3079 0604
    fdni@novonordisk.com

    Lars Borup Jacobsen 
    +45 3075 3479
    lbpj@novonordisk.com

    Daniel Bohsen
    +45 3079 6376
    dabo@novonordisk.com

    Jannick Lindegaard (US)
    +1 609 235 8567
    jlis@novonordisk.com

 

 

 

 

 

 

 

 

 

 

 

 



    Novo Nordisk A/S 
    Novo Allé
    Telephone:
    CVR no:

    Investor Relations 
    2880 Bagsværd
    +45 4444 8888
    24 25 67 90

     
    Denmark
    Internet:
     

     
     
    www.novonordisk.com
     

     
     
     

     
     
    Company announcement No 2 / 2014

     
     
     
     
     

 



    
 
    
 
    

 

 

SIGNATURES

Pursuant to the requirements of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly
authorized.



    Date: January 13, 2014
    
        
NOVO
        NORDISK A/S
        
Lars Rebien Sørensen,
        
President and Chief Executive Officer